Personalis (NASDAQ:PSNL) Trading 14.8% Higher – Still a Buy?

Personalis, Inc. (NASDAQ:PSNL)’s share price traded up 14.8% during mid-day trading on Thursday . The stock traded as high as $11.00 and last traded at $11.0750. 413,681 shares changed hands during trading, a decline of 69% from the average session volume of 1,327,764 shares. The stock had previously closed at $9.65.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the stock. Wall Street Zen lowered shares of Personalis from a “hold” rating to a “sell” rating in a report on Saturday, January 3rd. Morgan Stanley upped their price objective on shares of Personalis from $9.00 to $11.00 and gave the stock an “equal weight” rating in a research note on Monday, December 1st. Needham & Company LLC raised their price objective on shares of Personalis from $7.00 to $10.00 and gave the stock a “buy” rating in a report on Wednesday, November 5th. Guggenheim lifted their target price on shares of Personalis from $6.00 to $12.00 and gave the company a “buy” rating in a research note on Tuesday, November 11th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Personalis in a research report on Wednesday, October 8th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $10.57.

Personalis Stock Performance

The company has a market capitalization of $1.02 billion, a price-to-earnings ratio of -13.01 and a beta of 1.96. The business’s 50-day simple moving average is $8.93 and its 200-day simple moving average is $7.41.

Personalis (NASDAQ:PSNL) last posted its quarterly earnings results on Tuesday, November 4th. The company reported ($0.24) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.04. Personalis had a negative net margin of 106.92% and a negative return on equity of 38.25%. The business had revenue of $14.50 million during the quarter, compared to the consensus estimate of $13.31 million. On average, analysts forecast that Personalis, Inc. will post -1.4 earnings per share for the current year.

Insider Buying and Selling at Personalis

In other Personalis news, CEO Christopher M. Hall sold 29,612 shares of the stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $8.99, for a total value of $266,211.88. Following the transaction, the chief executive officer owned 148,486 shares of the company’s stock, valued at approximately $1,334,889.14. This represents a 16.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Aaron Tachibana sold 103,668 shares of the firm’s stock in a transaction dated Tuesday, November 25th. The stock was sold at an average price of $10.78, for a total value of $1,117,541.04. Following the transaction, the chief financial officer owned 164,458 shares in the company, valued at approximately $1,772,857.24. This trade represents a 38.66% decrease in their position. The disclosure for this sale is available in the SEC filing. 3.80% of the stock is owned by company insiders.

Institutional Investors Weigh In On Personalis

Several large investors have recently bought and sold shares of PSNL. Legal & General Group Plc bought a new position in shares of Personalis during the second quarter worth $30,000. Ameritas Investment Partners Inc. acquired a new stake in Personalis during the 2nd quarter worth $34,000. BNP Paribas Financial Markets lifted its holdings in Personalis by 406.4% during the second quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock worth $42,000 after acquiring an additional 5,177 shares in the last quarter. Alpha Wealth Funds LLC acquired a new position in Personalis in the second quarter valued at about $66,000. Finally, Farther Finance Advisors LLC acquired a new stake in shares of Personalis during the third quarter worth about $66,000. Institutional investors own 61.91% of the company’s stock.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.